Boston Scientific Corporation (NYSE:BSX) insider has recently participated in insider trading activity. SVP & Pres, Interven Cardio, Ballinger Kevin J. sold 7,616 shares for $132,290 via one transaction Feb 17. Another notable insider trading was done by Dockendorff Charles J on Feb 12, who is the Director. The insider acquired 30,000 shares at an average price of $16.49. Moreover, an insider selling of 6,216 shares was carried out by Prange Karen, SVP&Pres, Uro & Pelvic Health, on Feb 08. Following the transaction, the insider now owns 23,647 shares in total. EVP, GC & Chief Admin Officer Pratt Timothy A. sold 7,160 shares for $126,549 through one transaction Jan 08. Following this sale, this insider’s stake in the company comprises 303,776 shares, priced at $5,227,985 as of Thursday.
The stock has experienced a total of 24 insider trades in the past three months. These trades include 22 sell activities and 2 buy trades. Furthermore, over the past 12 months, the stock was traded 140 times by insiders. In 111 of these trades, the insider was a seller while an employee of the company was the buyer in just 29 instances.
Boston Scientific Corporation (BSX) on February 8, 2016 announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific criteria, as outlined in the agency’s final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the WATCHMAN™ LAAC Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries.
“We are very pleased CMS has established national coverage for this life-changing therapy for Medicare beneficiaries who have a reason to seek an alternative to long-term anticoagulation,” said Mike Mahoney, president and chief executive officer, Boston Scientific. “The final decision reflects more than a decade of robust clinical evidence and will facilitate additional data collection via a prospective national registry.”
The WATCHMAN Device, the first and only percutaneous LAAC therapy approved by the U.S. Food and Drug Administration (FDA) in March 2015, is indicated for patients with non-valvular atrial fibrillation (AF) who are at high stroke risk, suitable for warfarin, and are seeking an alternative to long-term warfarin therapy.
According to the NCD, CMS will cover percutaneous LAAC therapy when specific conditions are met. CMS adopted the majority of physician and professional medical society feedback received in the 30-day public comment period, specifically as it relates to patient coverage criteria and future data collection requirements.
Medicare beneficiaries account for the overwhelming majority of patients deemed candidates for the WATCHMAN Device. The remaining population is represented by private payers. Prior to the CMS final decision, a number of private payers, including several Blue Cross Blue Shield plans, have updated their policies to now cover the WATCHMAN Device.
0 yorum:
Yorum Gönder